ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
82.125
-0.19%
Bitcoin
67,366.76
-1.16%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) News

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CADL
DateTimeSourceHeadlineSymbolCompany
07/19/20248:31AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/19/20248:29AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/19/20248:28AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/19/20248:24AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/17/20247:32AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/17/20247:31AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/17/20247:29AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/17/20247:27AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/15/20248:36AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/15/20248:35AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/15/20248:34AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/15/20248:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/11/20247:38AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/11/20247:37AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/11/20247:36AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
07/11/20247:33AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CADLCandel Therapeutics Inc
06/18/20248:00AMGlobeNewswire Inc.Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:CADLCandel Therapeutics Inc
06/11/20248:00AMGlobeNewswire Inc.Candel Therapeutics to Join Russell 3000® IndexNASDAQ:CADLCandel Therapeutics Inc
05/30/20245:20PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CADLCandel Therapeutics Inc
05/30/20244:30PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CADLCandel Therapeutics Inc
05/30/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/30/20248:00AMGlobeNewswire Inc.FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
05/24/20247:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
05/23/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/23/20245:00PMGlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
05/22/20248:00AMGlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
05/20/20248:00AMGlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
05/14/20248:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
05/14/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/14/20248:00AMGlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CADL

Your Recent History

NYSE
HYT
BlackRock Corporate High...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved